噻托溴铵与异丙托溴铵联合舒利迭治疗中重度COPD患者疗效比较

目的：研究噻托溴铵干粉制剂及异丙托溴铵气雾制剂联合舒利迭治疗中重度COPD患者的疗效及安全性。方法：48名确诊为稳定期的中重度COPD患者随机分为噻托溴铵＋舒利迭组、异丙托溴铵＋舒利迭组及舒利迭组。治疗前及经治疗1、3个月后分别观察临床症状、生活质量评分、FEV1及6min步行距离（6MWD）。结果：三组COPD患者在吸入治疗后临床症状、生活质量、FEV1及6MWD明显改善,而联合M受体阻断剂时其改善作用更显著（P〈0.05）,且噻托溴铵干粉制剂优于异丙托溴铵气雾剂。结论：老年中重度COPD患者可考虑噻托溴铵及舒利迭联合吸入,提高疗效及安全性。

Comparison of therapeutic effects of tiotropium inhalation capsules and ipratropium metered dose inhaler in patient with moderate-severe chronic obstructive pulmonary disease

Objective:To study the efficacy and safety of Tiotropium Inhalation Capsules and Ipratropium metered dose in-haler in patient with moderate-severe chronic obstructive pulmonary disease. Methods: 48 patients with stable moderate-severe chronic obstructive pulmonary disease were randomly divided into 3 groups of Tiotropium Seretide, Ipratropium Seretide and Seretide. Clinic symptom, life quality score, FEV1 and 6 mins walk distant were measured before and 1 month, 3 month after treatment. Results: Clinic symptom, life quality score, FEV1 and 6 mins walk distant were improved in all groups compare with that before treatment, especially in groups of Tiotropium Seretide and Ipratropium Seretide. Tiotropium was more efficient than Ipratropium (P<0.05). Conclusion: The joint usage of Tiotropium and Seretide in patients with moderate-severe chronic obstructive pulmonary disease can improve the efficacy and safety.